Immune resistance can develop during tumor development, or intrinsic resistance, and after PD-1 blockade 1, or acquired resistance, attributed primarily to T cell exhaustion 6,13–16 and a dysregulated tumor microenvironment (TME) 16,17. This evidence concerns the gene PDCD1 and neoplasm.